Pfizer Inc.'s Besponsa (inotuzumab ozogamicin), an orphan drug for acute lymphocytic leukemia, has been given the green light in Europe, spelling good news for the drug's impending US regulatory decision. Once the recommendation is accepted by the European Commission it will represent the first regulatory approval for Besponda worldwide.
In its April round of decisions, the European Medicines Agency's scientific committee, the CHMP, granted Pfizer's drug a positive opinion...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?